Date: 2014-09-15
Type of information: Nomination
Compound:
Company: ImmunoGen (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On September 15, 2014, ImmunoGen, a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology,announced the appointment of Sandra E. Poole as Senior Vice President, Technical Operations. Prior to ImmunoGen, Ms. Poole had a 15-year career with Genzyme that spanned a wealth of bio-manufacturing-related functions with increasing responsibility, including heading up technology development, overseeing the construction, start-up, tech transfer and approval of a fully integrated manufacturing operation in Belgium and, most recently, leading Genzyme\'s global network of biologic manufacturing sites.
Prior to joining Genzyme in 1999, Ms. Poole oversaw process development and played a key role in establishing technical operations at Canadian-based Biomira, Inc.
Financial terms:
Latest news:
